Skip to main content

Advertisement

Log in

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

  • Letter to the Editor
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent macular edema. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-017-3624-y

    Google Scholar 

  2. Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506

    Article  CAS  PubMed  Google Scholar 

  3. Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 148:266–271

    Article  Google Scholar 

  4. Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 168(2):290–291

    PubMed  Google Scholar 

  6. Călugaru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol 174(2):175–176

    Article  PubMed  Google Scholar 

  7. Călugăru D, Călugăru M (2017) Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. Eur J Ophthalmol. doi:10.5301/ejo.5000898

    Google Scholar 

  8. Călugăru D, Călugăru M (2016) Comments to: long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26(6):171–172

    Google Scholar 

Download references

Acknowledgements

The authors have full control of the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mihai Călugăru.

Ethics declarations

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Disclosure

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Călugăru, D., Călugăru, M. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255, 1451–1452 (2017). https://doi.org/10.1007/s00417-017-3669-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3669-y

Keywords

Navigation